Two days later, 1 × 106 B6-derived CD8+ TCXCR4 or TControl (allo-TCXCR4 or allo-TControl) were given i.v. to separate cohorts of tumor-bearing mice and the antitumor effects compared with controls not receiving T cells. This evidence concerns the gene CD8A and neoplasm.